

Jay H Traverse

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3404856/jay-h-traverse-publications-by-year.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

91
papers

5,660
citations

33
h-index

75
g-index

103
ext. papers

6,560
ext. citations

8.7
avg, IF

4.87
L-index

#	Paper	IF	Citations
91	Dare to dream? Cell-based therapies for heart failure after DREAM-HF: Review and roadmap for future clinical study. <i>American Heart Journal Plus</i> , 2022 , 13, 100118		
90	Challenges and outcomes of the double kissing crush stenting technique: Insights from the PROGRESS-BIFURCATION registry.. <i>Catheterization and Cardiovascular Interventions</i> , 2022 ,	2.7	1
89	Reparative cell therapy for the heart: critical internal appraisal of the field in response to recent controversies. <i>ESC Heart Failure</i> , 2021 , 8, 2306-2309	3.7	2
88	A Phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRNCONCERT-HF trial. <i>European Journal of Heart Failure</i> , 2021 , 23, 661-674	12.3	26
87	Rate of Incomplete Revascularization Following Coronary Artery Bypass Grafting at a Single Institution Between 2007 and 2017. <i>American Journal of Cardiology</i> , 2021 , 144, 33-36	3	1
86	Effect of cardiosphere-derived cells on segmental myocardial function after myocardial infarction: ALLSTAR randomised clinical trial. <i>Open Heart</i> , 2021 , 8,	3	5
85	Temporal changes in patient characteristics and outcomes in ST-segment elevation myocardial infarction 2003-2018. <i>Catheterization and Cardiovascular Interventions</i> , 2021 , 97, 1109-1117	2.7	8
84	Outcomes With Combined Laser Atherectomy and Intravascular Brachytherapy in Recurrent Drug-Eluting Stent In-Stent Restenosis. <i>Cardiovascular Revascularization Medicine</i> , 2021 , 22, 29-33	1.6	3
83	Outcomes of intravascular brachytherapy for recurrent drug-eluting in-stent restenosis. <i>Catheterization and Cardiovascular Interventions</i> , 2021 , 97, 32-38	2.7	6
82	Multidisciplinary shock team is associated with improved outcomes in patients undergoing ECPR. <i>International Journal of Artificial Organs</i> , 2021 , 44, 310-317	1.9	2
81	Coronary Intravascular Brachytherapy for Recurrent Coronary Drug-Eluting Stent In-Stent Restenosis: A Systematic Review and Meta-Analysis. <i>Cardiovascular Revascularization Medicine</i> , 2021 , 23, 28-35	1.6	4
80	Point of care, bone marrow mononuclear cell therapy in ischemic heart failure patients personalized for cell potency: 12-month feasibility results from CardiAMP heart failure roll-in cohort. <i>International Journal of Cardiology</i> , 2021 , 326, 131-138	3.2	5
79	Recommendations for Nomenclature and Definition Of Cell Products Intended for Human Cardiovascular Use. <i>Cardiovascular Research</i> , 2021 ,	9.9	2
78	Comparison of Outcomes of Patients with vs without Previous Coronary Artery Bypass Graft Surgery Presenting with ST-Segment Elevation Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2021 , 154, 33-40	3	0
77	Epicardial delivery of XC001 gene therapy for refractory angina coronary treatment (The EXACT Trial): Rationale, design, and clinical considerations. <i>American Heart Journal</i> , 2021 , 241, 38-49	4.9	1
76	CD34 cell therapy significantly reduces adverse cardiac events, health care expenditures, and mortality in patients with refractory angina. <i>Stem Cells Translational Medicine</i> , 2020 , 9, 1147-1152	6.9	10
75	Clinical Characteristics and Outcomes of STEMI Patients With Cardiogenic Shock and Cardiac Arrest. <i>JACC: Cardiovascular Interventions</i> , 2020 , 13, 1211-1219	5	22

74	Meta-analysis of short- and long-term efficacy of mononuclear cell transplantation in patients with myocardial infarction. <i>American Heart Journal</i> , 2020 , 220, 155-175	4.9	4
73	Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients: The CCTRN SENECA Trial. <i>JACC: CardioOncology</i> , 2020 , 2, 581-595	3.8	12
72	Intracoronary ALlogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR): a randomized, placebo-controlled, double-blinded trial. <i>European Heart Journal</i> , 2020 , 41, 3451-3458	9.5	35
71	Impaired therapeutic efficacy of bone marrow cells from post-myocardial infarction patients in the TIME and LateTIME clinical trials. <i>PLoS ONE</i> , 2020 , 15, e0237401	3.7	1
70	First-in-Man Study of a Cardiac Extracellular Matrix Hydrogel in Early and Late Myocardial Infarction Patients. <i>JACC Basic To Translational Science</i> , 2019 , 4, 659-669	8.7	90
69	Coronary revascularization and use of hemodynamic support in acute coronary syndromes. <i>Hellenic Journal of Cardiology</i> , 2019 , 60, 165-170	2.1	2
68	Response by Traverse and Garberich to Letter Regarding Article, "NHLBI-Sponsored Randomized Trial of Postconditioning During Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction". <i>Circulation Research</i> , 2019 , 124, e57-e58	15.7	
67	Prevalence, Trends, and Outcomes of Higher-Risk Percutaneous Coronary Interventions Among Patients Without Acute Coronary Syndromes. <i>Cardiovascular Revascularization Medicine</i> , 2019 , 20, 289-292	1.6	5
66	NHLBI-Sponsored Randomized Trial of Postconditioning During Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. <i>Circulation Research</i> , 2019 , 124, 769-778	15.7	25
65	Incidence, predictors, management and outcomes of coronary perforations. <i>Catheterization and Cardiovascular Interventions</i> , 2019 , 93, 48-56	2.7	19
64	The CardiAMP Heart Failure trial: A randomized controlled pivotal trial of high-dose autologous bone marrow mononuclear cells using the CardiAMP cell therapy system in patients with post-myocardial infarction heart failure: Trial rationale and study design. <i>American Heart Journal</i> , 2018 , 201, 141-148	4.9	15
63	Impact of sleep deprivation on the outcomes of percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2018 , 92, 1118-1125	2.7	3
62	Autologous CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials. <i>European Heart Journal</i> , 2018 , 39, 2208-2216	9.5	46
61	Rationale and Design of the CONCERT-HF Trial (Combination of Mesenchymal and c-kit Cardiac Stem Cells As Regenerative Therapy for Heart Failure). <i>Circulation Research</i> , 2018 , 122, 1703-1715	15.7	72
60	New or presumed new left bundle branch block in patients with suspected ST-elevation myocardial infarction. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018 , 7, 208-217	4.3	9
59	Revascularization in "no option" patients with refractory angina: Frequency, etiology and outcomes. <i>Catheterization and Cardiovascular Interventions</i> , 2018 , 92, 1215-1219	2.7	7
58	Rationale and Design of the SENECA (StEm cell iNjECTION in cAncer survivors) Trial. <i>American Heart Journal</i> , 2018 , 201, 54-62	4.9	15
57	TIME Trial: Effect of Timing of Stem Cell Delivery Following ST-Elevation Myocardial Infarction on the Recovery of Global and Regional Left Ventricular Function: Final 2-Year Analysis. <i>Circulation Research</i> , 2018 , 122, 479-488	15.7	36

56	Expecting the unexpected: preventing and managing the consequences of coronary perforations. <i>Expert Review of Cardiovascular Therapy</i> , 2018 , 16, 805-814	2.5	6
55	Meta-analysis of the impact of successful chronic total occlusion percutaneous coronary intervention on left ventricular systolic function and reverse remodeling. <i>Journal of Interventional Cardiology</i> , 2018 , 31, 562-571	1.8	30
54	Evaluation of Cell Therapy on Exercise Performance and Limb Perfusion in Peripheral Artery Disease: The CCTRN PACE Trial (Patients With Intermittent Claudication Injected With ALDH Bright Cells). <i>Circulation</i> , 2017 , 135, 1417-1428	16.7	29
53	Peripheral Blood Cytokine Levels After Acute Myocardial Infarction: IL-1 β and IL-6-Related Impairment of Bone Marrow Function. <i>Circulation Research</i> , 2017 , 120, 1947-1957	15.7	27
52	ALLogeneic Heart STem Cells to Achieve Myocardial Regeneration (ALLSTAR) Trial: Rationale and Design. <i>Cell Transplantation</i> , 2017 , 26, 205-214	4	69
51	Contemporary Arterial Access in the Cardiac Catheterization Laboratory. <i>JACC: Cardiovascular Interventions</i> , 2017 , 10, 2233-2241	5	45
50	Circulating Biomarkers to Identify Responders in Cardiac Cell therapy. <i>Scientific Reports</i> , 2017 , 7, 4419	4.9	14
49	Identification of cardiovascular risk factors associated with bone marrow cell subsets in patients with STEMI: a biorepository evaluation from the CCTRN TIME and LateTIME clinical trials. <i>Basic Research in Cardiology</i> , 2017 , 112, 3	11.8	11
48	Bone marrow cell characteristics associated with patient profile and cardiac performance outcomes in the LateTIME-Cardiovascular Cell Therapy Research Network (CCTRN) trial. <i>American Heart Journal</i> , 2016 , 179, 142-50	4.9	14
47	Identification of Bone Marrow Cell Subpopulations Associated With Improved Functional Outcomes in Patients With Chronic Left Ventricular Dysfunction: An Embedded Cohort Evaluation of the FOCUS-CCTRN Trial. <i>Cell Transplantation</i> , 2016 , 25, 1675-1687	4	23
46	The Misguided Regulation of Cardiac Emergencies: The Rise of the IRB-Industrial Complex and the Increasing Risk to Cardiovascular Research and Our Patients. <i>Circulation Research</i> , 2016 , 119, 1063-1066	15.7	1
45	The RENEW Trial: Efficacy and Safety of Intramyocardial Autologous CD34(+) Cell Administration in Patients With Refractory Angina. <i>JACC: Cardiovascular Interventions</i> , 2016 , 9, 1576-85	5	78
44	Bioabsorbable Intracoronary Matrix for Prevention of Ventricular Remodeling After Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 715-23	15.1	61
43	A Phase II Dose-Escalation Study of Allogeneic Mesenchymal Precursor Cells in Patients With Ischemic or Nonischemic Heart Failure. <i>Circulation Research</i> , 2015 , 117, 576-84	15.7	141
42	Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial. <i>European Heart Journal</i> , 2015 , 36, 2228-38	9.5	114
41	Bone marrow characteristics associated with changes in infarct size after STEMI: a biorepository evaluation from the CCTRN TIME trial. <i>Circulation Research</i> , 2015 , 116, 99-107	15.7	49
40	Detailed analysis of bone marrow from patients with ischemic heart disease and left ventricular dysfunction: BM CD34, CD11b, and clonogenic capacity as biomarkers for clinical outcomes. <i>Circulation Research</i> , 2014 , 115, 867-74	15.7	50
39	Impact of intracoronary bone marrow cell therapy on left ventricular function in the setting of ST-segment elevation myocardial infarction: a collaborative meta-analysis. <i>European Heart Journal</i> , 2014 , 35, 989-98	9.5	97

38	One-year follow-up of intracoronary stem cell delivery on left ventricular function following ST-elevation myocardial infarction. <i>JAMA - Journal of the American Medical Association</i> , 2014 , 311, 301-2	27.4	26
37	Safety and efficacy of ixmyelocel-T: an expanded, autologous multi-cellular therapy, in dilated cardiomyopathy. <i>Circulation Research</i> , 2014 , 115, 730-7	15.7	48
36	Percutaneous Coronary Intervention in Spontaneous Coronary Artery Dissection: Role of Intravascular Ultrasound. <i>Cardiology and Therapy</i> , 2014 , 3, 61-6	2.8	4
35	Preinfarction angina reduces infarct size in ST-elevation myocardial infarction treated with percutaneous coronary intervention. <i>Circulation: Cardiovascular Interventions</i> , 2013 , 6, 52-8	6	39
34	Long-term survival in patients with refractory angina. <i>European Heart Journal</i> , 2013 , 34, 2683-8	9.5	104
33	Of mice and men: the quest to determine a circadian basis for myocardial protection in ischemia/reperfusion injury. <i>Circulation Research</i> , 2013 , 112, e115-7	15.7	8
32	Factors affecting the turnaround time for manufacturing, testing, and release of cellular therapy products prepared at multiple sites in support of multicenter cardiovascular regenerative medicine protocols: a Cardiovascular Cell Therapy Research Network (CCTRN) study. <i>Transfusion</i> , 2012 , 52, 2225-33	2.9	5
31	Using biomaterials to improve the efficacy of cell therapy following acute myocardial infarction. <i>Journal of Cardiovascular Translational Research</i> , 2012 , 5, 67-72	3.3	14
30	Effect of the use and timing of bone marrow mononuclear cell delivery on left ventricular function after acute myocardial infarction: the TIME randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 308, 2380-9	27.4	295
29	Cell tracking and the development of cell-based therapies: a view from the Cardiovascular Cell Therapy Research Network. <i>JACC: Cardiovascular Imaging</i> , 2012 , 5, 559-65	8.4	15
28	Circadian dependence of infarct size and left ventricular function after ST elevation myocardial infarction. <i>Circulation Research</i> , 2012 , 110, 105-10	15.7	99
27	Effect of transendocardial delivery of autologous bone marrow mononuclear cells on functional capacity, left ventricular function, and perfusion in chronic heart failure: the FOCUS-CCTRN trial. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 307, 1717-26	27.4	338
26	A randomized study of transendocardial injection of autologous bone marrow mononuclear cells and cell function analysis in ischemic heart failure (FOCUS-HF). <i>American Heart Journal</i> , 2011 , 161, 1078-87.e3	4.9	144
25	Is the measurement of left ventricular ejection fraction the proper end point for cell therapy trials? An analysis of the effect of bone marrow mononuclear stem cell administration on left ventricular ejection fraction after ST-segment elevation myocardial infarction when evaluated by cardiac magnetic resonance imaging. <i>American Heart Journal</i> , 2011 , 162, 671-7	4.9	32
24	Long-term follow-up of patients undergoing postconditioning during ST-elevation myocardial infarction. <i>Journal of Cardiovascular Translational Research</i> , 2011 , 4, 92-8	3.3	66
23	Effect of intracoronary delivery of autologous bone marrow mononuclear cells 2 to 3 weeks following acute myocardial infarction on left ventricular function: the LateTIME randomized trial. <i>JAMA - Journal of the American Medical Association</i> , 2011 , 306, 2110-9	27.4	314
22	Intramyocardial, autologous CD34+ cell therapy for refractory angina. <i>Circulation Research</i> , 2011 , 109, 428-36	15.7	364
21	Results of a phase 1, randomized, double-blind, placebo-controlled trial of bone marrow mononuclear stem cell administration in patients following ST-elevation myocardial infarction. <i>American Heart Journal</i> , 2010 , 160, 428-34	4.9	76

20	Multicenter cell processing for cardiovascular regenerative medicine applications: the Cardiovascular Cell Therapy Research Network (CCTRN) experience. <i>Cytotherapy</i> , 2010 , 12, 684-91	4.8	27
19	LateTIME: a phase-II, randomized, double-blinded, placebo-controlled, pilot trial evaluating the safety and effect of administration of bone marrow mononuclear cells 2 to 3 weeks after acute myocardial infarction. <i>Texas Heart Institute Journal</i> , 2010 , 37, 412-20	0.8	45
18	Rationale and design for TIME: A phase II, randomized, double-blind, placebo-controlled pilot trial evaluating the safety and effect of timing of administration of bone marrow mononuclear cells after acute myocardial infarction. <i>American Heart Journal</i> , 2009 , 158, 356-63	4.9	66
17	A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. <i>Journal of the American College of Cardiology</i> , 2009 , 54, 2277-86	15.1	1038
16	Cell therapy for acute myocardial infarction--where do we go from here?. <i>Journal of Cardiovascular Translational Research</i> , 2008 , 1, 64-70	3.3	3
15	Intramyocardial transplantation of autologous CD34+ stem cells for intractable angina: a phase I/IIa double-blind, randomized controlled trial. <i>Circulation</i> , 2007 , 115, 3165-72	16.7	450
14	Effect of K ⁺ ATP channel and adenosine receptor blockade during rest and exercise in congestive heart failure. <i>Circulation Research</i> , 2007 , 100, 1643-9	15.7	11
13	A regional system to provide timely access to percutaneous coronary intervention for ST-elevation myocardial infarction. <i>Circulation</i> , 2007 , 116, 721-8	16.7	373
12	Measurement of myocardial free radical production during exercise using EPR spectroscopy. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2006 , 290, H2453-8	5.2	12
11	Clinical, angiographic, and interventional follow-up of patients with aortic-saphenous vein graft connectors. <i>Circulation</i> , 2003 , 108, 452-6	16.7	47
10	Inhibition of NO production increases myocardial blood flow and oxygen consumption in congestive heart failure. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2002 , 282, H2278-83	5.2	18
9	Coronary nitric oxide production in response to exercise and endothelium-dependent agonists. <i>Circulation</i> , 2000 , 101, 2526-31	16.7	37
8	Effect of sildenafil on coronary active and reactive hyperemia. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2000 , 279, H2319-25	5.2	21
7	Cyclic nucleotide phosphodiesterase type 5 activity limits blood flow to hypoperfused myocardium during exercise. <i>Circulation</i> , 2000 , 102, 2997-3002	16.7	49
6	Role of K ⁽⁺⁾ (ATP) channels and adenosine in regulation of coronary blood flow in the hypertrophied left ventricle. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1999 , 277, H617-25	5.2	10
5	Nitroglycerin dilates coronary collateral vessels during exercise after blockade of endogenous NO production. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 1999 , 277, H918-23	5.2	5
4	Regulation of myocardial blood flow by oxygen consumption is maintained in the failing heart during exercise. <i>Circulation Research</i> , 1999 , 84, 401-8	15.7	27
3	Epithelioid hemangioendothelioma of the thoracic aorta resulting in aortic obstruction and congestive heart failure. <i>Circulation</i> , 1999 , 100, 564-5	16.7	16

- | | | | |
|---|--|------|----|
| 2 | Nitric oxide inhibition impairs blood flow during exercise in hearts with a collateral-dependent myocardial region. <i>Journal of the American College of Cardiology</i> , 1998 , 31, 67-74 | 15.1 | 24 |
| 1 | Effect of beta-adrenergic receptor blockade on blood flow to collateral-dependent myocardium during exercise. <i>Circulation</i> , 1995 , 91, 1560-7 | 16.7 | 17 |